297 related articles for article (PubMed ID: 37916308)
41. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
Front Immunol; 2018; 9():1301. PubMed ID: 29930558
[TBL] [Abstract][Full Text] [Related]
42. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
43. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
44. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
[TBL] [Abstract][Full Text] [Related]
45. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
46. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
48. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
49. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
50. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
51. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
52. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
53. Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer.
Lei X; Wang Y; Broens C; Borst J; Xiao Y
Int Rev Cell Mol Biol; 2024; 382():145-179. PubMed ID: 38225102
[TBL] [Abstract][Full Text] [Related]
54. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
55. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
56. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
57. Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System.
Wu L; Xie W; Li Y; Ni Q; Timashev P; Lyu M; Xia L; Zhang Y; Liu L; Yuan Y; Liang XJ; Zhang Q
Adv Sci (Weinh); 2022 Jun; 9(17):e2105376. PubMed ID: 35396800
[TBL] [Abstract][Full Text] [Related]
58. Targeting toll-like receptors on T cells as a therapeutic strategy against tumors.
Ding R; Jiao A; Zhang B
Int Immunopharmacol; 2022 Jun; 107():108708. PubMed ID: 35306281
[TBL] [Abstract][Full Text] [Related]
59. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
60. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
